John E. Bishop - 28 Feb 2022 Form 4 Insider Report for Forma Therapeutics Holdings, Inc.

Role
SVP, Chief Technology Officer
Signature
/s/ Jeannette Potts, as Attorney-in-Fact
Issuer symbol
N/A
Transactions as of
28 Feb 2022
Net transactions value
$0
Form type
4
Filing time
02 Mar 2022, 16:14:30 UTC
Previous filing
15 Jun 2021
Next filing
14 Oct 2022
SEC
View on sec.gov

Quoteable Key Fact

"John E. Bishop filed Form 4 for Forma Therapeutics Holdings, Inc. on 02 Mar 2022."

Quick Takeaways

  • This page summarizes John E. Bishop's Form 4 filing for Forma Therapeutics Holdings, Inc..
  • 2 reported transactions and 1 derivative row are listed below.
  • Filing timestamp: 02 Mar 2022, 16:14.

What Changed

  • Previous filing in this sequence was filed on 15 Jun 2021.
  • Current net transaction value: $0.

Why This Matters

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Source Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

See Original Filing

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction FMTX Common Stock Award $0 +25,950 +118% $0.000000 47,950 28 Feb 2022 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction FMTX Stock Option (Right to Buy) Award $0 +38,930 $0.000000 38,930 28 Feb 2022 Common Stock 38,930 $9.86 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These shares represented restricted stock units and will be settled into common stock upon vesting. Each restricted stock unit would be converted into one share of FMTX common stock.
F2 25% of the shares subject to the stock option shall vest on February 28, 2023, and the remainder of the shares vest in equal monthly installments for a period of 36 months thereafter.